HealthCare Global Enterprises (HCG) Q4 15/16 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 15/16 earnings summary
16 Oct, 2026Executive summary
FY16 consolidated revenue from operations rose 12% YoY to Rs. 5,819.77 million; EBITDA increased 17.6% to Rs. 896.48 million, while PAT was Rs. 12.21 million.
Listed on BSE and NSE on March 30, 2016; the IPO comprised 11.6 million fresh shares and 18.2 million offer-for-sale shares, for a total issue size of Rs. 6,496.4 million.
Operated 17 cancer centres, three diagnostic centres, one day-care chemotherapy centre and two multispecialty hospitals; treated 37,315 new cancer patients in FY16.
Financial highlights
Total revenue was Rs. 5,854.28 million, up 11.68% YoY; revenue from operations grew 12.05% to Rs. 5,819.77 million.
EBITDA was Rs. 896.48 million versus Rs. 762.40 million; EBITDA margin expanded 70 bps to 15.4% from 14.7%.
PBT before exceptional items rose to Rs. 110.71 million from Rs. 75.76 million; reported PAT increased to Rs. 12.21 million from Rs. 8.34 million.
Exceptional items were Rs. 60.69 million, including Rs. 44.28 million from the BNH closure and Rs. 16.41 million loss on disposal of HCG TVH investments.
Standalone operations revenue increased 12% to Rs. 4,702.13 million; standalone EBITDA before exceptional items was Rs. 704.29 million, with a 15% margin.
Outlook and guidance
Targeting 26 cancer care centres and nine fertility centres by FY18; nine new comprehensive cancer centres were under development, with operations expected by end-FY18.
Plans to expand cancer services through new centres, capacity additions, partnerships and acquisitions; Ahmedabad centre expansion included LINAC, PET-CT, MRI and gamma-camera equipment.
Plans to establish African cancer centres, initially in Kenya, Tanzania and Uganda; a definitive agreement with CDC provides for investment in HCG Africa.
Milann expansion planned through greenfield centres, partnerships and selective acquisitions; Indian IVF cycles forecast to rise from 100,000 in 2015 to 260,000 by 2020.
Ind AS financial reporting was scheduled to begin April 1, 2016; IT plans included private-cloud infrastructure and a centralized EMR integrated with HIS and ERP systems.
Latest events from HealthCare Global Enterprises
- Revenue and margins advanced as patient volumes rose and expansion continued.HCG
Q4 22/23 - FY17 revenue grew 19.8%, EBITDA 23.9%, and PAT returned to profit.HCG
Q4 16/17 - Revenue grew 18.7%, while new-centre losses pressured margin and profit.HCG
Q4 17/18 - Revenue and EBITDA grew, but COVID-19 and lease costs deepened losses; ₹5,128m was raised after year-end.HCG
Q4 19/20 - Revenue grew, but expansion costs drove a ₹248 million attributable loss.HCG
Q4 18/19 - FY22 revenue and operating EBITDA surged as earnings returned to profit.HCG
Q4 21/22 - COVID disruption widened losses; equity funding enabled substantial deleveraging.HCG
Q4 20/21 - Revenue up 13% YoY, adjusted EBITDA margin at 19.4%, PAT up 190%, with broad-based growth.HCG
Q1 26/27 - Q2 FY25 revenue up 15% and EBITDA up 21%, driven by digital and expansion strategies.HCG
Q2 2025